| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Medpace Holdings, Inc. Common Stock
$587.52
+4.36 (+0.75%)
Market Cap
16.40 B
EPS
17.37
P/E Ratio
33.82 $
Value Trade
140.13 M
-0.57 %
Week
-1.61 %
1 Month
25.67 %
3 Month
29.51 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
159.49 K
52 Week Range
373 - 677.90
% held by Insiders
19.48 %
% held by Institutions
89.66 %
Enterprise Value
15.90 B
Total Shares
27.92 M
Short %
7.43 %
Float Shares
22.50 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Medpace Holdings, Inc. Common Stock
84Total events
0Upcoming
0Tier-1 (high impact)
2016 – 2026Coverage
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MEDP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MEDP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-12-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-12-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-12-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-MEDP
Jul 22, 2026▲ +14.7%on this news
Medpace Holdings, Inc. Reports Second Quarter 2026 Results
Medpace Holdings, Inc. reported a significant revenue increase of 17.2% for the second quarter of 2026, reaching $707.3 million compared to $603.3 million in the same period last year. This growth was consistent even when adjusted for currency fluctuations. The company continues to show strong financial performance.
Read more →-MEDP
Jul 7, 2026Behind the Breakthroughs: Rare Disease Q&A with Lauren Shannon
The article features a Q&A with Lauren Shannon, an Advanced Clinical Practitioner at Medpace, discussing her experiences in rare disease clinical trials. It highlights the unique challenges of conducting trials in this area and the importance of integrating clinical practice with research. Shannon emphasizes the need for caregiver involvement and the potential impact of innovative therapies on patient care.
Read more →-MEDP
Jun 30, 2026Inside the Lab: Spotlight on Molecular Innovation – Q&A with El Mustapha Bahassi, PhD
The article features an interview with El Mustapha Bahassi, PhD, discussing the evolving role of molecular testing in clinical trials at Medpace. He highlights the company's investment in advanced technologies, such as automated molecular platforms and liquid biopsy innovations. Bahassi emphasizes the importance of collaboration across laboratory functions to ensure efficient and accurate processing of clinical samples.
Read more →-MEDP
Jun 16, 2026Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
Medpace Holdings, Inc. has announced that it will report its financial results for the second quarter of 2026 on July 22, 2026. This announcement provides stakeholders with a timeline for when to expect the financial performance details of the company. The report will likely include insights into the company's operations and financial health.
Read more →-MEDP
Jun 4, 2026Advancing Gene Therapy Innovation in Ophthalmology Trials
The article discusses the advancements in gene therapy for ophthalmology, highlighting the transition from concept to clinical application. It emphasizes the unique challenges of ophthalmic gene therapy trials, including patient recruitment and specialized delivery methods. Medpace's role in facilitating these trials through a comprehensive approach is also detailed, showcasing their expertise in navigating regulatory pathways and operational complexities.
Read more →-MEDP
Jun 1, 2026Expert Perspectives on the Transforming Diabetes Clinical Trial Landscape
Medpace is actively transforming diabetes clinical trials by integrating innovative strategies, particularly in type 1 diabetes with cell and gene therapies. At the ADA Scientific Sessions, Medpace's experts will discuss their support for sponsors navigating complex diabetes programs. Their fully integrated model enhances operational efficiency and data quality, ensuring high-quality trial execution.
Read more →-MEDP
May 27, 2026Inside the Lab: Building Histology Capabilities for Modern Clinical Trials – Q&A with Rob McGee, MD, PhD
Medpace is enhancing its histology and anatomic pathology services to support complex clinical trials. Dr. Robert McGee discusses the establishment of a robust histology program and the shift towards digital pathology. This integration allows for improved collaboration across laboratory functions, supporting a variety of therapeutic areas, including oncology and metabolic diseases.
Read more →-MEDP
May 26, 2026Q&A with Medpace’s Two New Neurology Experts
Medpace has welcomed two new neurologists, Dr. Teresa León Colombo and Dr. Raul Barahona-Hernando, who bring extensive experience in neurodegenerative and neuromuscular diseases. Their insights into clinical development and patient care aim to enhance the design and execution of neuroscience trials. They highlight the importance of personalized approaches and innovative therapies in addressing complex neurological conditions.
Read more →-MEDP
Apr 22, 2026Medpace Holdings, Inc. Reports First Quarter 2026 Results
Medpace Holdings, Inc. has reported its financial results for the first quarter of 2026. The article does not provide specific details about the performance metrics or any significant events related to the results. The information appears to be limited and lacks context.
Read more →-MEDP
Apr 22, 2026Investor Contact Lauren Morris 283-227-6409 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 283-227-6367 m.maley medpace.com Medpace Holdings, Inc. Reports First Quarter 2026 Results Revenue of $70
Medpace Holdings, Inc. reported its financial results for the first quarter of 2026, highlighting substantial revenue growth of 26.5% compared to the previous year, amounting to $706.6 million. The company's net new business awards also increased by 23.7%, resulting in a net book-to-bill ratio of 0.88x. However, despite growing revenue and EBITDA, the net income margin saw a decline, and a key executive's upcoming resignation was announced, potentially affecting future strategy. The company forecasts continued growth for 2026 with revenues projected between $2.755 billion and $2.855 billion.
Read more →-MEDP
Mar 25, 2026Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026
Medpace Holdings, Inc. announced it will report its first quarter 2026 financial results on April 22, 2026. A conference call will follow on April 23, 2026, at 9:00 a.m. ET for discussion of these results. Interested participants must register in advance, and a webcast will also be available.
Read more →-MEDP
Feb 10, 2026▼ -15.9%on this news
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results
Medpace Holdings, Inc. reported strong financial results for Q4 and full year 2025, with revenues increasing by 32% year-over-year in Q4 and 20% for the full year. The company also announced a positive outlook for 2026, projecting revenue growth between 8.9% and 12.8%. However, total direct costs and SG&A expenses have risen, impacting net income margins.
Read more →-MEDP
Feb 9, 2026Investor Contact Lauren Morris 283-227-6409 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 283-227-6367 m.maley medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results
Medpace Holdings, Inc. reported strong financial results for the fourth quarter and full year ended December 31, 2025. Revenue increased by 32.0% to $708.5 million, while net new business awards rose by 39.1%, resulting in a net book-to-bill ratio of 1.04. GAAP net income for Q4 2025 was $135.1 million, reflecting an increase from the previous year. For 2026, the company projects revenue growth between 8.9% and 12.8%, indicating continued optimism in its business outlook.
Read more →-MEDP
Oct 22, 2025Investor Contact Lauren Morris 283-227-6409 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 283-227-6367 m.maley medpace.com Medpace Holdings, Inc. Reports Third Quarter 2025 Results Revenue of $65
Medpace Holdings, Inc. reported third quarter 2025 results showing a revenue of $659.9 million, a 23.7% increase compared to the same quarter last year. Net new business awards reached $789.6 million, reflecting a growth of 47.9%, leading to a net book-to-bill ratio of 1.20x. The company's GAAP net income for the quarter was $111.1 million, translating to $3.86 per diluted share. Overall, Medpace's strong performance highlights its successful expansion and financial stability despite a slight dip in net income margin.
Read more →-MEDP
Jul 21, 2025Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 513.579.9911 x12831 m.maley medpace.com Medpace Holdings, Inc. Reports Second Quarter 2025 Results
Medpace Holdings, Inc. reported its financial results for the second quarter of 2025, highlighting a revenue growth of 14.2% year-over-year, totaling $603.3 million. The company achieved net new business awards of $620.5 million, reflecting a 12.6% increase over the prior-year period. Despite this positive performance, Medpace experienced a slight decline in its net income margin from 16.7% to 15.0%. Additionally, the backlog showed a decrease of 1.8% from June 2024 to June 2025. For the full year, the company forecasts revenue growth between 14.7% to 19.5% over 2024.
Read more →-MEDP
Apr 21, 2025Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 513.579.9911 x12831 m.maley medpace.com Medpace Holdings, Inc. Reports First Quarter 2025 Results
Medpace Holdings, Inc. reported its financial results for the first quarter of 2025, highlighting a 9.3% increase in revenue to $558.6 million compared to the previous year. However, net new business awards saw a decline of 18.8%, leading to a book-to-bill ratio of 0.90x. Despite these challenges, the company achieved a net income of $114.6 million, reflecting an increase from prior year figures. Looking ahead, Medpace projects its 2025 revenue to grow slightly, estimating between $2.140 billion and $2.240 billion.
Read more →-MEDP
Feb 10, 2025Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 513.579.9911 x12831 m.maley medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Yea
Medpace Holdings, Inc. reported its financial results for the fourth quarter and full year of 2024, showing a 7.7% increase in revenue compared to the same period in 2023. The company's GAAP net income rose to $117 million for Q4 2024, compared to $78.3 million in the previous year. However, net new business awards decreased by 13.8%, impacting the net book-to-bill ratio, which stood at 0.99x. Looking ahead, Medpace projects revenue growth of up to 4.8% for 2025.
Read more →-MEDP
Oct 21, 2024Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 513.579.9911 x12831 m.maley medpace.com Medpace Holdings, Inc. Reports Third Quarter 2024 Results
Medpace Holdings, Inc. reported its third quarter 2024 financial results, highlighting an 8.3% increase in revenue to $533.3 million compared to the prior year. The company experienced significant growth in GAAP net income, which rose to $96.4 million, alongside a 31.7% increase in EBITDA, reaching $118.8 million. However, net new business awards saw a decline of 12.7%, resulting in a stable net book-to-bill ratio of 1.00x. Medpace forecasts a revenue range of $2.090 billion to $2.130 billion for the full year 2024, indicating continued growth expectations despite the recent decline in new business awards.
Read more →-MEDP
Jul 22, 2024Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports Second Quarter 2024 Resul
Medpace Holdings, Inc. reported its financial results for the second quarter of 2024, showcasing a 14.6% increase in revenue to $528.1 million compared to the same period last year. The company achieved significant net income of $88.4 million, resulting in a notable increase in net income margin. However, net new business awards saw a slight decline of 4.1%, indicating a potential challenge in maintaining growth momentum. Despite the increase in operating costs, the company generated strong cash flow, reinforcing its financial stability.
Read more →-MEDP
Apr 22, 2024Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports First Quarter 2024 Result
Medpace Holdings, Inc. reported strong financial results for the first quarter of 2024, with revenues of $511 million, up 17.7% from the previous year. Net new business awards also rose by 10.8%, resulting in a book-to-bill ratio of 1.20x. The company reported GAAP net income of $102.6 million, up from $72.9 million the year prior, while EBITDA increased by 24.6% to $115.7 million. Medpace forecasts a revenue growth of 14% to 16.7% for the full year 2024, projecting total revenues to range between $2.15 billion and $2.2 billion.
Read more →-MEDP
Feb 12, 2024Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Y
Medpace Holdings, Inc. reported strong financial results for the fourth quarter and full year of 2023, with revenues reaching $498.4 million for Q4, a 26.5% increase from the previous year. The company also achieved net new business awards of $614.7 million in Q4 2023, which translates to a net book-to-bill ratio of 1.23x. For the full year, revenue grew by 29.2% to $1.885 billion, and a positive forecast was given for 2024 with expected revenues between $2.150 and $2.200 billion. However, there was a noted decline in the net income margin from 17.4% to 15.7%, and total direct costs increased significantly year-over-year.
Read more →-MEDP
Oct 23, 2023Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports Third Quarter 2023 Result
Medpace Holdings, Inc. has reported strong third quarter results for 2023, showing a revenue increase of 28.3% year-over-year to $492.5 million. The company's net new business awards also rose by 29.9%, contributing to a robust book-to-bill ratio of 1.24x. Despite modest growth in EBITDA, Medpace achieved a net income margin of 14.3%. The company is optimistic with its financial guidance, forecasting full-year revenue between $1.870 billion and $1.890 billion for 2023.
Read more →-MEDP
Jul 24, 2023Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports Second Quarter 2023 Resul
Medpace Holdings, Inc. reported strong financial results for the second quarter of 2023, with revenue increasing by 31.2% year-over-year to $460.9 million. The company also saw an increase in net new business awards, totaling $574.8 million, resulting in a net book-to-bill ratio of 1.25x. Despite positive growth in revenue and net income, the net income margin experienced a slight decline. Medpace forecasts continued growth for 2023, with expected revenue between $1.840 billion and $1.880 billion.
Read more →-MEDP
Apr 24, 2023Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports First Quarter 2023 Result
Medpace Holdings, Inc. reported robust financial results for the first quarter of 2023, with revenue rising 31.2% year-over-year to $434.1 million. The company achieved a net new business award of $555.8 million, reflecting increased market demand. However, the net income margin slightly decreased from 18.5% to 16.8%, while total direct costs grew significantly. Despite these challenges, Medpace has provided a favorable guidance for the full year, expecting revenue growth of up to 23.6%.
Read more →-MEDP
Oct 24, 2022Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports Third Quarter 2022 Result
l.morris medpace.com j.hopkins medpace.com Medpace Holdings, Inc. Reports Third Quarter 2022 Results Revenue of $383.7 million in the third quarter of 2022 increased 29.8% from revenue of $295.6 million for the comparable prior-year period, representing a backlog conversion ra
Read more →-MEDP
Jul 25, 2022Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.com FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 j.hopkins@medpace.com Medpace Holdings, Inc. Reports Second Quarter 2022 Res
l.morris@medpace.com j.hopkins@medpace.com Medpace Holdings, Inc. Reports Second Quarter 2022 Results -Revenue of $351.2 million in the second quarter of 2022 increased 26.2% from revenue of $278.3 million for the comparable prior-year period, representing a backlog conversion
Read more →-MEDP
Apr 25, 2022Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.co m FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 j.hopkins@medpace.com Medpace Holdings, Inc. Reports First Quarter 2022 Res
l.morris@medpace.com j.hopkins@medpace.com Medpace Holdings, Inc. Reports First Quarter 2022 Results -Revenue of $330.9 million in the first quarter of 2022 increased 27.3% from revenue of $260.0 million for the comparable prior-year period, representing a backlog conversion r
Read more →-MEDP
Feb 14, 2022Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.co m FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 j.hopkins@medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Ful
l.morris@medpace.com j.hopkins@medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Results -Revenue of $308.6 million in the fourth quarter of 2021 increased 18.8% from revenue of $259.7 million for the comparable prior-year period, representing a back
Read more →-MEDP
Oct 25, 2021Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.co m FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 j.hopkins@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2021 Res
l.morris@medpace.com j.hopkins@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2021 Results Revenue of $295.6 million in the third quarter of 2021 increased 28.3% from revenue of $230.4 million for the comparable prior-year period, representing a backlog conversion ra
Read more →-MEDP
Jul 26, 2021Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.com Media Contact: Julie Hopkins 513.579.9911 x12627 j.hopkins@medpace.com Medpace Holdings, Inc. Announces Senior Leadership Changes Appointment of Je
Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.com Media Contact: Julie Hopkins 513.579.9911 x12627 j.hopkins@medpace.com Medpace Holdings, Inc. Announces Senior Leadership Changes Appointment of Jesse Geiger as President and Kevin Brady as Chief F
Read more →-MEDP
Apr 26, 2021Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.com Media Contact: Julie Hopkins 513.579.9911 x12627 j.hopkins@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports First Quarter 2021 Resu
l.morris@medpace.com j.hopkins@medpace.com Medpace Holdings, Inc. Reports First Quarter 2021 Results CINCINNATI, OHIO, April 26, 2021-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the first quarter ended March 31, 2021. First Quarte
Read more →-MEDP
Feb 15, 2021Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.com Media Contact: Julie Hopkins 513.579.9911 x12627 j.hopkins@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Fourth Quarter and Full
l.morris@medpace.com j.hopkins@medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2020 Results CINCINNATI, OHIO, February 15, 2021-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the fourth quarter and full year en
Read more →-MEDP
Oct 26, 2020Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.com Media Contact: Julie Hopkins 513.579.9911 x12627 j.hopkins@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Third Quarter 2020 Resu
l.morris@medpace.com j.hopkins@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2020 Results CINCINNATI, OHIO, October 26, 2020-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended September 30, 2020. Third
Read more →-MEDP
Jul 27, 2020Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 j.hopkins@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Second Quarter 2020 Results Ȃ
Medpace Holdings, Inc. j.hopkins@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Second Quarter 2020 Results CINCINNATI, OHIO, July 27, 2020-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the second quarter ended June
Read more →-MEDP
Apr 28, 2020Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 j.hopkins@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports First Quarter 2020 Results •
Medpace Holdings, Inc. j.hopkins@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports First Quarter 2020 Results CINCINNATI, OHIO, April 28, 2020-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the first quarter ended March
Read more →-MEDP
Feb 24, 2020Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 j.hopkins@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2019
Medpace Holdings, Inc. j.hopkins@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Results CINCINNATI, OHIO, February 24, 2020-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the fourth
Read more →-MEDP
Oct 28, 2019Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 j.hopkins@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Third Quarter 2019 Results •
Medpace Holdings, Inc. j.hopkins@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2019 Results CINCINNATI, OHIO, October 28, 2019-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended Sep
Read more →-MEDP
Jul 29, 2019Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 j.hopkins@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Second Quarter 2019 Results Ȃ
Medpace Holdings, Inc. j.hopkins@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Second Quarter 2019 Results CINCINNATI, OHIO, July 29, 2019-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the second quarter ended June
Read more →-MEDP
Apr 29, 2019Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 j.hopkins@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports First Quarter 2019 Results •
Medpace Holdings, Inc. j.hopkins@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports First Quarter 2019 Results CINCINNATI, OHIO, April 29, 2019-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the first quarter ended March
Read more →-MEDP
Feb 25, 2019Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 j.hopkins@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2018
Medpace Holdings, Inc. j.hopkins@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2018 Results CINCINNATI, OHIO, February 25, 2019-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the fourth
Read more →-MEDP
Oct 29, 2018Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 j.hopkins@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Third Quarter 2018 Results •
Medpace Holdings, Inc. j.hopkins@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2018 Results CINCINNATI, OHIO, October 29, 2018-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended Sep
Read more →-MEDP
Jul 30, 2018Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 j.hopkins@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Second Quarter 2018 Results Ȃ
Medpace Holdings, Inc. j.hopkins@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Second Quarter 2018 Results CINCINNATI, OHIO, July 30, 2018-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the second quarter ended June
Read more →-MEDP
Apr 30, 2018Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 j.hopkins@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports First Quarter 2018 Results •
Medpace Holdings, Inc. j.hopkins@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports First Quarter 2018 Results CINCINNATI, OHIO, April 30, 2018-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the first quarter ended March
Read more →-MEDP
Feb 26, 2018Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 j.hopkins@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2017
Medpace Holdings, Inc. j.hopkins@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2017 Results CINCINNATI, OHIO, February 26, 2018-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the fourth
Read more →-MEDP
Oct 30, 2017Mary Kuramoto Medpace Holdings, Inc. 513.579.9911 x12523 m.kuramoto@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Third Quarter 2017 Results Ȃ
Medpace Holdings, Inc. m.kuramoto@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2017 Results CINCINNATI, OHIO, October 30, 2017-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended Se
Read more →-MEDP
Aug 16, 2017Mary Kuramoto Medpace Holdings, Inc. 513.579.9911 x12523 m.kuramoto@medpace.com FOR IMMEDIATE RELEASE Investor Contact: investor@medpace.com Medpace Holdings, Inc. Announces Stock Repurchase Agreement with
Media Contact: Mary Kuramoto Medpace Holdings, Inc. 513.579.9911 x12523 m.kuramoto@medpace.com FOR IMMEDIATE RELEASE Investor Contact: investor@medpace.com Medpace Holdings, Inc. Announces Stock Repurchase Agreement with Cinven CINCINNATI - August 16, 2017 - Medpace Holdings,
Read more →-MEDP
Jul 31, 2017Mary Kuramoto Medpace Holdings, Inc. 513.579.9911 x12523 m.kuramoto@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Second Quarter 2017 Results  
Medpace Holdings, Inc. m.kuramoto@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Second Quarter 2017 Results CINCINNATI, OHIO, July 31, 2017-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the second quarter ended Jun
Read more →-MEDP
May 1, 2017Mary Kuramoto Medpace Holdings, Inc. 513.579.9911 x12523 m.kuramoto@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports First Quarter 2017 Results; Board
Medpace Holdings, Inc. m.kuramoto@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports First Quarter 2017 Results; Board Authorizes $50 Million Share Repurchase Program CINCINNATI, OHIO, May 1, 2017-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announc
Read more →-MEDP
Feb 27, 2017Mary Kuramoto Medpace Holdings, Inc. 513.579.9911 x2523 m.kuramoto@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2016
Medpace Holdings, Inc. m.kuramoto@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2016 Results CINCINNATI, OHIO, February 27, 2017-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the fourth
Read more →-MEDP
Nov 3, 2016Mary Kuramoto Medpace Holdings, Inc. 513.579.9911 x2523 m.kuramoto@medpace.com Investor Contact: investor@medpace.com FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Third Quarter 2016 Results •
Medpace Holdings, Inc. m.kuramoto@medpace.com investor@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2016 Results CINCINNATI, OHIO, November 3, 2016-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended Se
Read more →-MEDP
Aug 16, 2016Mary Kuramoto Medpace Holdings, Inc. 513.579.9911 x2523 m.kuramoto@medpace.com Investor Contact: investor@medpace.com Medpace Holdings, Inc. Announces Closing of Initial Public Offering
Medpace Holdings, Inc. m.kuramoto@medpace.com investor@medpace.com Medpace Holdings, Inc. Announces Closing of Initial Public Offering CINCINNATI, Ohio, August 16, 2016 Medpace Holdings, Inc. (Nasdaq: MEDP) ( Medpace ) today announced the closing of its initial public offeri
Read more →Competitive Position
How MEDP ranks across every disease it competes inCompetitive Position is a premium feature
See how MEDP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial